157 results about "Thrombocytopenic purpura" patented technology

Elevated number of Circulating Endothelial Cells (CEC) have been implicated in disease conditions associated with the formation or destruction of blood vessels such as acute coronary syndrome, thrombocytopenic purpura, sickle cell disease, sepsis, lupus, nephrotic syndromes, rejection of organ transplants, surgical trauma and cancer. This invention provides a method for assessing the levels of CEC which vary between different studies using a sensitive enrichment, imaging, and enumberation analysis. CD146 is one of the most specific endothelium-associated cell-surface antigens which can be used in image cytometry. CEC analysis provides an essential tool in prognostic / diagnostic evaluation in the clinic.

Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (SLE), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, Sjogren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity, The present invention also enables methods for treating cancers that are mediated, dependent on or associated with p110δ activity, including but not restricted to leukemias, such as Acute Myeloid leukaemia (AML) Myelo-dysplastic syndrome (MDS) myelo-proliferative diseases (MPD) Chronic Myeloid Leukemia (CML) T-cell Acute Lymphoblastic leukaemia (T-ALL) B-cell Acute Lymphoblastic leukaemia (B-ALL) Non Hodgkins Lymphoma (NHL) B-cell lymphoma and solid tumors, such as breast cancer.

CD16A binding proteins useful for the reduction of a deleterious immune response asre described. In one aspect, humanized anti-cd16A antibodies, optionally lacking effector function, are used for the treatment of immune disorders such as idiopathic thrombocytopenic purpura and autoimme hemolytic anemia.

Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (SLE), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, Sjoegren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity, The present invention also enables methods for treating cancers that are mediated, dependent on or associated with p110δ activity, including but not restricted to leukemias, such as Acute Myeloid leukaemia (AML) Myelodysplastic syndrome (MDS) myelo-proliferative diseases (MPD) Chronic Myeloid Leukemia (CML) T-cell Acute Lymphoblastic leukaemia (T-ALL) B-cell Acute Lymphoblastic leukaemia (B-ALL) Non Hodgkins Lymphoma (NHL) B-cell lymphoma and solid tumors, such as breast cancer.

Substituted bicyclic heteroaryls having the general formulaand compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (SLE), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, Sjoegren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity, The present invention also enables methods for treating cancers that are mediated, dependent on or associated with p110δ activity, including but not restricted to leukemias, such as Acute Myeloid leukaemia (AML) Myelo-dysplastic syndrome (MDS) myelo-proliferative diseases (MPD) Chronic Myeloid Leukemia (CML) T-cell Acute Lymphoblastic leukaemia (T-ALL) B-cell Acute Lymphoblastic leukaemia (B-ALL) Non Hodgkins Lymphoma (NHL) B-cell lymphoma and solid tumors, such as breast cancer.

Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (SLE), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, Sjoegren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity, The present invention also enables methods for treating cancers that are mediated, dependent on or associated with p110δ activity, including but not restricted to leukemias, such as Acute Myeloid leukemia (AML) Myelodysplastic syndrome (MDS) myelo-proliferative diseases (MPD) Chronic Myeloid Leukemia (CML) T-cell Acute Lymphoblastic leukaemia (T-ALL) B-cell Acute Lymphoblastic leukaemia (B-ALL) Non Hodgkins Lymphoma (NHL) B-cell lymphoma and solid tumors, such as breast cancer.

Substituted bicyclic heteroaryls having the structures:and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (SLE), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, Sjoegren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity, The present invention also enables methods for treating cancers that are mediated, dependent on or associated with p110δ activity, including but not restricted to leukemias, such as Acute Myeloid leukaemia (AML) Myelo-dysplastic syndrome (MDS) myelo-proliferative diseases (MPD) Chronic Myeloid Leukemia (CML) T-cell Acute Lymphoblastic leukaemia (T-ALL) B-cell Acute Lymphoblastic leukaemia (B-ALL) Non Hodgkins Lymphoma (NHL) B-cell lymphoma and solid tumors, such as breast cancer.

The present invention discloses preparation process and application of rosemary acid, and features that rosemary acid and its derivative and mixture may be prepared into preparation for antagonizing tumor of digestive tract and other tumor and synergizing and attenuating tumor treating chemotherapeutic medicine and radiotherapy. Medicine preparation of rosemary acid and its derivative and mixture may be used directly in treating primary or secondary thrombocytopenic purpura and leucopenia and thrombocytopenia caused by chemotherapy or radiotherapy. The present invention also provides process of extracting high purity rosemary acid and its derivative and mixture from Sarcandra glabra as the plant material.

The invention relates to the field of medicines and especially relates to an application of antiplatelet thrombolysin in preparation of a medicine for treating thrombotic thrombocytopenic purpura (TTP). The antiplatelet thrombolysin limits adhesion and aggregation of platelets, recovers levels of the platelets, erythrocytes and hemoglobin, reduces level of lactic dehydrogenase and effectively inhibits thrombocytopenia and cleaved-cell hemolyticanemia, thereby treating the TTP. The antiplatelet thrombolysin has great clinical application prospect.

Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (SLE), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, Sjoegren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity, The present invention also enables methods for treating cancers that are mediated, dependent on or associated with p110δ activity, including but not restricted to leukemias, such as Acute Myeloid leukaemia (AML) Myelo-dysplastic syndrome (MDS) myelo-proliferative diseases (MPD) Chronic Myeloid Leukemia (CML) T-cell Acute Lymphoblastic leukaemia (T-ALL) B-cell Acute Lymphoblastic leukaemia (B-ALL) Non Hodgkins Lymphoma (NHL) B-cell lymphoma and solid tumors, such as breast cancer.

The invention provides a Chinese medicinal composition for treating anaphylactoid purpura and thrombocytopenic purpura. The Chinese medicinal composition comprises the following raw materials or extracts thereof: rehmannia root, rehmannia root, stir-fried white paeony root, raw sanguisorba root, hairyvein agrimonia herb and bud, patience dock root, Sinkiang arnebia root, indigowoad leaf, weeping forsythia, herba ecliptae, giant knotweed rhizome, cicada slough, densefruit pittany root-bark, raw cattail pollen, peanut coat, tea begonia and Phnom Penh malus spectabilis. The Chinese medicinal composition for treating the anaphylactoid purpura and the thrombocytopenic purpura is quick in effectiveness, definite in a curative effect and free from toxic and side effects, and the anaphylactoid purpura and the thrombocytopenic purpura are difficult to relapse.

The invention relates to a preparation method of a Chinese herbal medicine for treating idiopathic thrombocytopenic purpura, belonging to the technical field of the Chinese herbal medicine preparation method. At present, glucocorticoid such as prednisone is adopted to treat idiopathic thrombocytopenic purpura and is easy to bring side effect. The technical proposal is that: steep rhinoceros horn, root of rehmannia, root of herbaceous peony, herba cirsii, thistle, Chinese arborvitae twig, root of madder, palm, rhizoma imperatae, Chinese rhubarb, gardenia, gromwell, red peony root, pulsatilla chinensis, flos imperatae, loofah, spiranthes sinensis, herba ecliptae, cockscomb, Japanese dock root and tree peony bark in water and boil with slow fire to make into the Chinese herbal medicine for treating idiopathic thrombocytopenic purpura. The Chinese herbal medicine for treating idiopathic thrombocytopenic purpura has the advantages of having a stable curative effect after oral intake and avoiding anaphylactic reaction and gastrointestinal reaction caused by adopting western medicine as well as a plurality of restriction set by using glucocorticoid.

The invention relates to the development of an animal model for testing various agents in the treatment of a clotting disorder. More specifically, the invention relates to the use of ultra-large molecular weight multimers of von Willebrand factor (VWF) in various mouse strains to induce thrombotic thrombocytopenic purpura (TTP)-like symptoms for the development of a mouse model of TTP. The invention also provides methods for generating such animal disease models and screening methods for identifying biologically active compounds which are effective in the treatment of TTP.

The invention provides a medicament for treating thrombocytolytic purpura, which comprises the following raw materials by weight part: 15-25 parts of rhizoma smilacis glabrae, 20-30 parts of honeysuckle, 10-20 parts of radix arnebiae seu lithospermi, 10-20 parts of rehmannia root, 10-20 parts of white mulberry root-bark, 25-35 parts of oyster, 10-20 parts of clerodendrum bungei, 10-20 parts of yellow celery and 5-15 parts of cicada slough. In the invention, the natural herbal drugs capable of clearing away heat and toxic materials, activating blood and dissolving stasis, cooling and nourishingblood and stopping bleeding, removing water and eliminating swellings are selected from the medicinal treasury of China, and play roles of clearing away heat, cooling the blood, stopping the bleeding, eliminating spots, activating blood and dissolving stasis, improving the microcirculation, dredging channels, diminishing pain, and the like according to a Chinese medicine theory formula. The medicament does not contain any chemical drugs, thereby being innoxious to human bodies; and the medicament is convenient to take, can enhance the resistance and the immunity of organisms and relieve pains of patients, and has obvious curative effect.